BioNTech (BNTX) recently experienced a 10% price increase in the last quarter, coinciding with the Health Canada's authorization of its variant-adapted COMIRNATY COVID-19 vaccine, a potential positive ...

CureVac Announces Financial Results for the Second Quarter and First Half of 2025 and Provides Business UpdatesEntered into a definitive Purchase Agreement pursuant to which BioNTech intends to ...

Parents in the United States who want to vaccinate their young children against Covid-19 this fall may face a growing set of ...

Patients in England with advanced head and neck cancer are being fast-tracked into a groundbreaking mRNA cancer vaccine trial, a ...

Investing.com -- GSK (NYSE: GSK) (LON: GSK) said on Monday that the U.S. Food and Drug Administration has accepted its ...

Californians are trading in their sun-filled coastal lives for this undiscovered paradise - as locals reveal the incredible ...

The tussle had centred on the development of mRNA jab technology, which was at the forefront of the fight against Covid-19.

This is the third cancer vaccine trial to be run through the NHS Cancer Vaccine Launch Pad, coordinated by the Southampton ...

People with head and neck cancer in England will be fast-tracked on to a clinical trial for a “potentially transformative” vaccine under new NHS plans.

Flutter Entertainment (FLTR) upped full-year guidance after a solid second quarter, with group revenue up 16 per cent to $4.2bn (£3.1bn) and adjusted Ebitda climbing 25 per cent to $919mn. Average ...

Recent developments have highlighted a major mRNA patent settlement involving BioNTech (BNTX) and CureVac, leading to a $370 million payment with GSK plc, which has added complexity to BioNTech's ...

UK pharma major GSK (LSE: GSK) today announced that, in connection with the mRNA patent settlement reached between CureVac ...